Drugs Made In America Acquisition Corp. (DMAA) shareholders
Close on Nov 13, 2026Market cap $264.62MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Drugs Made In America Acquisition LLC Joint filing with Lynn Stockwell (12.50%) | 4,188,780 | 12.50% | 13D (active) | Feb 18, 2025 |
| Karpus Management, Inc. | 2,507,817 | 10.33% | 13G (passive) amendment | Jun 30, 2026 |
| Mizuho Financial Group, Inc. | 2,058,605 | 8.50% | 13G (passive) amendment | Jun 30, 2026 |
| Polar Asset Management Partners Inc. | 1,900,000 | 5.70% | 13G (passive) | Mar 31, 2025 |
| Glazer Capital, LLC Joint filing with Paul J. Glazer (5.44%) | 1,822,952 | 5.44% | 13G (passive) | Mar 31, 2025 |
| Feis Equities LLC Joint filing with Lawrence M. Feis (5.08%) | 1,232,775 | 5.08% | 13G (passive) | Jun 18, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of DMAA | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Mizuho Securities USA LLC | 4,069,605 | – | $42.83M | +2,069,605 | 0.41% |
| Karpus Management, Inc. | 2,507,817 | – | $26.71M | −22,700 | 0.77% |
| Polar Asset Management Partners Inc. | 1,146,000 | – | $12.20M | −454,000 | 0.20% |
| Glazer Capital, LLC | 999,899 | – | $10.65M | −678,507 | 0.26% |
| Wolverine Asset Management LLC | 832,093 | – | $8.86M | −721,615 | 0.08% |
| Highbridge Capital Management LLC | 809,054 | – | $8.62M | −514,297 | 0.21% |
| First Trust Capital Management L.P. | 786,459 | – | $8.38M | −1,456,041 | 0.49% |
| Heights Capital Management, Inc | 648,083 | – | $6.90M | −1,917 | 1.59% |
| Westchester Capital Management, LLC | 581,790 | – | $6.20M | −1,087,210 | 0.30% |
| Clear Street Group Inc. | 382,440 | – | $1.65M | +28,392 | 0.00% |
| Aristeia Capital LLC | 350,000 | – | $3.73M | −531,716 | 0.05% |
| Sona Asset Management (US) LLC | 162,795 | – | $1.73M | – | 0.04% |
| RLH Capital LLC | 115,606 | – | $1.23M | −200,945 | 0.59% |
| Logan Stone Capital, LLC | 109,959 | – | $1.17M | New | 0.25% |
| Toronto Dominion Bank | 100,000 | – | $1.07M | −103,838 | 0.00% |
| Meteora Capital, LLC | 97,837 | – | $1.04M | −282,462 | 0.09% |
| Quarry LP | 65,551 | – | $698.12K | −201,000 | 0.06% |
| Geode Capital Management, LLC | 62,273 | – | $663.21K | – | 0.00% |
| JPMorgan Chase & Co | 49,891 | – | $531.34K | +10 | 0.00% |
| Dakota Wealth Management | 36,400 | – | $387.66K | – | 0.01% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|
| Q2 2026 | 23 | 14M | 1 / 3 | 15 / 17 | 2M | 11M |
| Q1 2026 | 39 | 23M | 6 / 7 | 7 / 6 | 3M | 3M |
| Q4 2025 | 39 | 23M | 4 / 11 | 7 / 1 | 2M | 1M |
| Q3 2025 | 37 | 22M | 11 / 6 | 9 / 5 | 3M | 1M |
| Q2 2025 | 32 | 21M | 11 / 7 | 6 / 2 | 5M | 3M |
| Q1 2025 | 24 | 20M | 24 / 0 | 0 / 0 | 20M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
2 funds held DMAA in Q2 2026, 0% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of DMAA | Value | % of fund | As of |
|---|---|---|---|---|---|
| First Trust Merger Arbitrage Fund | 675,366 | – | $7.19M | 0.44% | Jun 30, 2026 |
| First Trust Multi-Strategy Fund | 105,083 | – | $1.12M | 0.08% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | Latest filing |
|---|---|---|---|
| Lynn Stockwell | CEO and Exe. Chair of Board, Director, 10% owner | 4,188,780 | Feb 18, 2025 |
| Glenn C. Worman | CFO | 100,000 | Feb 3, 2025 |
| Catherine Do | Director | 100,000 | Feb 3, 2025 |
| Myron W. Shulgan | Director | 100,000 | Feb 3, 2025 |
| Sridhar G. Prasad | Director | 100,000 | Feb 3, 2025 |
| Made In America Acquisition LLC Drugs | 10% owner | 4,188,780 | Feb 18, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Lynn Stockwell CEO and Exe. Chair of Board, Director, 10% owner | Feb 18, 2025 | Buy | +30,000 | – | – | 4,188,780 |
| Made In America Acquisition LLC Drugs 10% owner | Feb 18, 2025 | Buy | +30,000 | – | – | 4,188,780 |
| Lynn Stockwell CEO and Executive COB, Director, 10% owner | Jan 29, 2025 | Buy | +400,000 | – | – | 10,257 |
| Lynn Stockwell CEO and Executive COB, Director, 10% owner | Jan 29, 2025 | Other | −400,000 | – | – | 9,857,143 |
| Lynn Stockwell CEO and Executive COB, Director, 10% owner | Jan 29, 2025 | Sale | −5,698,363 | – | – | 4,158,780 |
| Made In America Acquisition LLC Drugs 10% owner | Jan 29, 2025 | Other | −400,000 | – | – | 9,857,143 |
| Made In America Acquisition LLC Drugs 10% owner | Jan 29, 2025 | Sale | −5,698,363 | – | – | 4,158,780 |
| Made In America Acquisition LLC Drugs 10% owner | Jan 29, 2025 | Buy | +400,000 | – | – | 10,257,143 |
| Sridhar G. Prasad Director | Jan 29, 2025 | Other | +100,000 | – | – | 100,000 |
| Myron W. Shulgan Director | Jan 29, 2025 | Other | +100,000 | – | – | 100,000 |
| Catherine Do Director | Jan 29, 2025 | Other | +100,000 | – | – | 100,000 |
| Glenn C. Worman CFO | Jan 29, 2025 | Other | +100,000 | – | – | 100,000 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Drugs Made In America Acquisition's stock actually held short. Settlement fails (shares not delivered on time) peaked at 1,239 shares on Oct 14, 2026 over the last 90 days.
See a number that looks wrong?